This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Jazz (JAZZ) Enrolls First Patient in Psychiatric Disorder Study
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) enrolls the first patient in a phase II study to evaluate JZP150 for treating adults with post-traumatic stress disorder.
J&J (JNJ) Seeks FDA Approval for Myeloma Drug Teclistamab
by Zacks Equity Research
J&J (JNJ) submits a Biologics License Application, seeking approval for its bispecific antibody candidate teclistamab as a treatment option for the heavily pretreated multiple myeloma patients.
AstraZeneca (AZN) Closes Agreement for Eplontersen With Ionis
by Zacks Equity Research
AstraZeneca (AZN) closes its agreement with Ionis for jointly developing and commercializing eplontersen in the United States.
Kiniksa (KNSA) COVID-19 Study for ARDS Fails to Meet Main Goal
by Zacks Equity Research
Kiniksa (KNSA) reports that the phase III portion of mavrilimumab???s phase II/III study for COVID-related ARDS did not meet the primary efficacy endpoint.
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Gilead Sciences (GILD) and GlaxoSmithKline (GSK) have performed compared to their sector so far this year.
Can Veklury Sales Retain Momemtum for Gilead (GILD) in 2022?
by Zacks Equity Research
Solid sales from Veklury cushion Gilead (GILD) in 2021 amid COVID-19. However, new oral antivirals in the market might hurt sales. GILD now shifts focus to oncology as the virology space faces issues.
Ligand (LGND) Stock Surges 60% YTD: What's Driving the Rally?
by Zacks Equity Research
Strong demand for two of Ligand's (LGND) partnered drugs, AMGN's Krprolis and GILD's Veklury, is driving its royalties. This is likely to continue next year.
Pharma Stock Roundup: FDA Approves PFE & MRK's Oral Pills for COVID & Other Drugs
by Kinjel Shah
FDA approves Pfizer's (PFE) and Merck's (MRK) oral COVID antiviral pills and AstraZeneca's (AZN) asthma medicine, Tezspire (tezepelumab).
Novartis (NVS) Gets FDA Nod for Cosentyx's Label Expansion
by Zacks Equity Research
The FDA approves Novartis' (NVS) Cosentyx for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis.
AstraZeneca's (AZN) Ultomiris sBLA Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts and grants priority review to AstraZeneca's (AZN) sBLA for Ultomiris for treating adults with generalized myasthenia gravis. A decision is expected in the second quarter of 2022.
Lilly's (LLY) Eczema Study on Lebrikizumab Combo Meets Goal
by Zacks Equity Research
Eli Lilly's (LLY) pivotal phase III study on lebrikizumab in combination with topical corticosteroids meets the primary and key secondary endpoints.
Novartis (NVS) to Buy Gyroscope, Submits Herceptin Biosimilar to EMA
by Zacks Equity Research
Novartis (NVS) is set to acquire ocular gene therapy company Gyroscope Therapeutic. Generic arm Sandoz submits a marketing authorization application for a proposed biosimilar of Herceptin.
GlaxoSmithKline (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed the most recent trading day at $43.36, moving +0.7% from the previous trading session.
Glaxo (GSK) Gets FDA Nod for HIV Preventive Injectable Drug
by Zacks Equity Research
Glaxo's (GSK) Apretude is the first and only long-acting injectable therapy approved for HIV prevention or PrEP.
Sanofi (SNY) to Acquire Amunix, Boost Immuno-oncology Pipeline
by Zacks Equity Research
Sanofi (SNY) inks a deal to acquire privately-held Amunix Pharmaceuticals, which will add potentially transformative cancer therapies to its immuno-oncology pipeline.
Gilead's (GILD) Veklury Gets EC Nod for Use in Early COVID-19
by Zacks Equity Research
Gilead's (GILD) Veklury can now be used in the EU at the early stages of COVID-19 to help prevent disease progression in high-risk patients.
GSK vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
GSK vs. NVO: Which Stock Is the Better Value Option?
Amgen, AstraZeneca's Asthma Drug Tezepelumab Gets FDA Nod
by Zacks Equity Research
Amgen (AMGN) and AstraZeneca's (AZN) Tezspire is the only biologic medicine approved by the FDA to treat severe asthma with no phenotype limitation and irrespective of biomarker levels.
Vir (VIR), Glaxo's Xevudy Wins EC Approval for COVID-19
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) and partner GlaxoSmithKline obtain the European Commission's nod for Xevudy for the early treatment of COVID-19.
bluebird's (BLUE) BLA for CALD Therapy Gets Priority Review
by Zacks Equity Research
bluebird's (BLUE) filing for eli-cel, a gene-therapy to treat cerebral adrenoleukodystrophy, gets priority review from the FDA.
Novavax (NVAX) COVID Jab Gets WHO Nod for Emergency Use Listing
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine gets approval from WHO for emergency use listing. The vaccine is now pre-qualified for supply to numerous countries participating through the COVAX facility.
Omicron Variant Puts COVID-19 Antibody Treatments in Focus
by Zacks Equity Research
We take a look at the data reported so far on antibody treatments by Regeneron (REGN), AstraZeneca (AZN) and Vir (VIR) amid the Omicron variant scare. The results have been mixed mostly.
Merck's (MRK) Pneumococcal Vaccine Vaxneuvance Gets EU Nod
by Zacks Equity Research
Merck's (MRK) Vaxneuvance includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.
Jazz (JAZZ) Enrols First Patient in Essential Tremor Study
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) enrolls the first patient in a phase IIb study to evaluate JZP385 for essential tremor.
Lilly (LLY) Stock Up on Raised 2021 View, Upbeat 2022 Guidance
by Zacks Equity Research
Eli Lilly's (LLY) stock rallies after it raises 2021 profit and sales outlook and provides an upbeat financial guidance for the next year.